

**Amendments to the Specification:**

Please change the paragraph at page 17, lines 5-32, with the following:

Peptides particularly of interest for use in the present invention include laminin, which has the sequence

YIGSR

(SEQ ID NO: 7)

echistatin, which has the sequence

ECESGPCCRNCFLKEGTICKRARGDDMDDYCNGKTCDCPRNPHKGPAT

(SEQ ID NO: 8)

RGD, NGR and derivatives thereof having the sequences

RX<sub>1</sub>ETX<sub>2</sub>WX<sub>3</sub>

(SEQ ID NO: 9)

wherein X<sub>1</sub>, X<sub>2</sub>, and X<sub>3</sub> are any amino acid;

CX<sub>1</sub>X<sub>2</sub>RLDX<sub>3</sub>X<sub>4</sub>C

(SEQ ID NO: 11)

wherein X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub> and X<sub>4</sub> are any amino acid;

~~CXXRGDC~~

~~(SEQ ID NO: 12)~~

X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>RGDX<sub>4</sub>X<sub>5</sub>X<sub>6</sub>

(SEQ ID NO: 13)

wherein X<sub>1</sub>, X<sub>3</sub>, X<sub>4</sub>, and X<sub>6</sub> are capable of forming a bridge (by disulfide bonds, peptide bonds or lactam bonds) and X<sub>2</sub> and X<sub>5</sub> are 1 to 5 amino acids;

CX<sub>2</sub>CRGDCX<sub>5</sub>C

(SEQ ID NO: 14)

wherein X<sub>2</sub> and X<sub>5</sub> are 1 to 5 amino acids;

~~X<sub>1</sub>X<sub>2</sub>DDX<sub>4</sub>X<sub>5</sub>X<sub>7</sub>X<sub>8</sub>~~

~~X<sub>1</sub>X<sub>2</sub>DDX<sub>5</sub>X<sub>6</sub>X<sub>7</sub>X<sub>8</sub>~~

(SEQ ID NOS: 15, 138-161)

wherein  $X_1$  and  $X_8$  each is an independently selected amino acid,  $X_2$  and  $X_7$  together equal 0 to 4 amino acids, each amino acid of which is independently selected,  $[X_4]X_5$  is selected from the group consisting of glycine and leucine, and  $[X_5]X_6$  is selected from the group consisting of tryptophan and leucine;

~~$X_1X_2X_3DDX_4X_5X_6X_7X_8$~~

$X_1X_2X_3DDX_6X_7X_8X_9X_{10}$

(SEQ ID NO: 16)

wherein  $X_1$  and  $[X_8]X_{10}$  each is an independently selected amino acid,  $X_2$  and  $[X_7]X_9$  together equal 0 to 3 amino acids, each amino acid of which is independently selected,  $X_3$  is selected from the group consisting of tryptophan and proline,  $[X_4]X_6$  is selected from the group consisting of glycine and leucine,  $[X_5]X_7$  is selected from the group consisting of tryptophan and leucine, and  $[X_6]X_8$  is selected from the group consisting of leucine, tryptophan, and methionine.

The substituents  ~~$X_1, X_2, X_3, X_4, X_5, X_6, X_7, \text{ and } X_8$~~ ,  $X_1, X_2, X_3, X_6, X_7, X_8, X_9, \text{ and } X_{10}$  are as defined in International applications WO 95/14714, published June 1, 1995 and WO 97/08203, published March 6, 1997 (corresponding to U.S. Pat. Nos. 5,627,263 and 5,817,750, respectively), which are incorporated by reference in their entirety.

Appl. No. 09/840,277  
Amdt. dated January \_\_\_, 2005  
Reply to Office Action of November 24, 2004

**Amendments to the Sequence Listing:**

The attached sequence listing replaces the original sequence listing filed in this matter.